List of Excipients in API BRINZOLAMIDE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing BRINZOLAMIDE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Alcon Laboratories Inc | AZOPT | brinzolamide | 0065-0275 | BENZALKONIUM CHLORIDE | |
| Alcon Laboratories Inc | AZOPT | brinzolamide | 0065-0275 | CARBOMER HOMOPOLYMER TYPE C | |
| Alcon Laboratories Inc | AZOPT | brinzolamide | 0065-0275 | EDETATE DISODIUM | |
| Alcon Laboratories Inc | AZOPT | brinzolamide | 0065-0275 | HYDROCHLORIC ACID | |
| Alcon Laboratories Inc | AZOPT | brinzolamide | 0065-0275 | MANNITOL | |
| Alcon Laboratories Inc | AZOPT | brinzolamide | 0065-0275 | SODIUM CHLORIDE | |
| Alcon Laboratories Inc | AZOPT | brinzolamide | 0065-0275 | SODIUM HYDROXIDE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing BRINZOLAMIDE
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Padagis US LLC | brinzolamide | 0574-4012 | BENZALKONIUM CHLORIDE |
| Padagis US LLC | brinzolamide | 0574-4012 | CARBOMER HOMOPOLYMER TYPE B |
| Padagis US LLC | brinzolamide | 0574-4012 | EDETATE DISODIUM |
| Padagis US LLC | brinzolamide | 0574-4012 | HYDROCHLORIC ACID |
| Padagis US LLC | brinzolamide | 0574-4012 | MANNITOL |
| Padagis US LLC | brinzolamide | 0574-4012 | SODIUM CHLORIDE |
| Padagis US LLC | brinzolamide | 0574-4012 | SODIUM HYDROXIDE |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for BRINZOLAMIDE
Excipient focus: BENZALKONIUM CHLORIDE
BRINZOLAMIDE drug variants containing BENZALKONIUM CHLORIDE
BRINZOLAMIDE drug variants not containing BENZALKONIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BORIC ACID
BRINZOLAMIDE drug variants containing BORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Alcon Laboratories Inc | brinzolamide/brimonidine tartrate | 0065-4147 |
| Novartis Pharmaceuticals Corporation | brinzolamide/brimonidine tartrate | 0078-0904 |
| >Company | >Ingredient | >NDC |
BRINZOLAMIDE drug variants not containing BORIC ACID
Excipient focus: CARBOMER HOMOPOLYMER TYPE B
BRINZOLAMIDE drug variants containing CARBOMER HOMOPOLYMER TYPE B
BRINZOLAMIDE drug variants not containing CARBOMER HOMOPOLYMER TYPE B
Excipient focus: CARBOMER HOMOPOLYMER TYPE C
BRINZOLAMIDE drug variants containing CARBOMER HOMOPOLYMER TYPE C
BRINZOLAMIDE drug variants not containing CARBOMER HOMOPOLYMER TYPE C
Excipient focus: EDETATE DISODIUM
BRINZOLAMIDE drug variants containing EDETATE DISODIUM
BRINZOLAMIDE drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Alcon Laboratories Inc | brinzolamide/brimonidine tartrate | 0065-4147 |
| Novartis Pharmaceuticals Corporation | brinzolamide/brimonidine tartrate | 0078-0904 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
BRINZOLAMIDE drug variants containing HYDROCHLORIC ACID
BRINZOLAMIDE drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
BRINZOLAMIDE drug variants containing MANNITOL
BRINZOLAMIDE drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
BRINZOLAMIDE drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Alcon Laboratories Inc | brinzolamide/brimonidine tartrate | 0065-4147 |
| Novartis Pharmaceuticals Corporation | brinzolamide/brimonidine tartrate | 0078-0904 |
| >Company | >Ingredient | >NDC |
BRINZOLAMIDE drug variants not containing PROPYLENE GLYCOL
Excipient focus: SODIUM CHLORIDE
BRINZOLAMIDE drug variants containing SODIUM CHLORIDE
BRINZOLAMIDE drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
BRINZOLAMIDE drug variants containing SODIUM HYDROXIDE
BRINZOLAMIDE drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TYLOXAPOL
BRINZOLAMIDE drug variants containing TYLOXAPOL
BRINZOLAMIDE drug variants not containing TYLOXAPOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
BRINZOLAMIDE drug variants containing WATER
BRINZOLAMIDE drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
